Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome:: Results of a randomized, double-blind, placebo-controlled study
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome:: Results of a randomized, double-blind, placebo-controlled study
复制标题
DOI：
10.1016/j.ahj.2004.07.041
复制
发表时间：
2005-03-01
影响因子：
4.8
通讯作者：
Badaracco, R
中科院分区：
文献类型：
--
作者：
Macin, SM;Perna, ER;Badaracco, R
背景C-反应蛋白（CRP）水平与心血管风险相关。我们评估的假设，阿托伐他汀可能有抗炎作用，在急性冠脉综合征（ACS）所示的CRP reduction.Methods这项研究是一个前瞻性的，随机的，双盲的，安慰剂对照研究的90个连续的患者入院48小时内发病的ACS与CRP水平>= 1.4 mg/dL。患者被分配接受阿托伐他汀40 mg/d或安慰剂治疗30天。在入组时、出院时和1个月后测量C反应蛋白水平、血脂谱、血清纤维蛋白原、白色细胞计数和红细胞沉降率。（平均年龄59.3 ± 13.4 vs 61.1 ± 11.5，P = ns）;心肌梗死52.3% vs 67.4%（P = ns）。两组中，中位基线CRP水平相当（5.97 +/- 6.2 vs 4.64 +/- 4.2 mg/dL，P = ns）。阿托伐他汀组出院时C反应蛋白水平低于对照组（1.68 +/- 1.65 vs 4.12 +/- 4.18 mg/dL），30天时C反应蛋白水平低于对照组（0.50 +/- 0.71 vs 2.91 +/- 2.68 mg/dL，均P
Background C-reactive protein (CRP) levels are associated with cardiovascular risk. We assessed the hypothesis that atorvastatin might have anti-inflammatory effects in acute coronary syndromes (ACS) as shown by CRP reduction.Methods This study was a prospective, randomized, double-blind, placebo-controlled study of 90 consecutive patients admitted within 48 hours of onset of ACS with CRP levels >= 1.4 mg/dL. Patients were assigned to atorvastatin 40 mg daily or placebo over 30 days. C-reactive protein levels, lipid profiles, serum fibrinogen, white cell count, and erythrocyte sedimentation rate were measured at entry, hospital discharge, and 1 month later.Results Baseline clinical characteristics did not differ between atorvastatin and placebo groups (mean age 59.3 +/- 13.4 vs 61.1 +/- 11.5, P = ns); myocardial infarction 52.3% versus 67.4% (P = ns). In both groups, median baseline CRP levels were comparable (5.97 +/- 6.2 vs 4.64 +/- 4.2 mg/dL, P = ns). C-reactive protein levels were lower in the atorvastatin group versus control group at discharge (1.68 +/- 1.65 vs 4.12 +/- 4.18 mg/dL) and at 30 days (0.50 +/- 0.71 vs; 2.91 +/- 2.68 mg/dL, both P